Standard therapy prevails in head & neck cancer trial
Source: www.medpagetoday.com Author: Charles Bankhead, Senior Editor, MedPage Today Neither a single immune checkpoint inhibitor nor a combination improved survival versus standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), an international randomized trial showed. Durvalumab (Imfinzi) alone led to a media overall survival (OS) of 7.6 months, and patients treated with the combination of durvalumab and tremelimumab had a median OS of 6.5 months. Both values were numerically lower than the 8.3-month median achieved with standard therapy, according to Robert L. Ferris, MD, of the University of Pittsburgh Hillman Cancer Center, and colleagues. In landmark analyses, both single-agent durvalumab led to numerically higher OS at 12, 18, and 24 months, and the combination had higher OS at 18 and 24 months. None of the differences achieved statistical significance versus standard of care, they reported in the Annals of Oncology. "Despite the apparent lack of benefit over standard of care, durvalumab clinical activity was in line with other checkpoint blockade agents in this setting," they wrote. "Although cross-trial comparisons should be approached with caution, median OS for durvalumab was similar to median OS for nivolumab (Opdivo) and pembrolizumab (Keytruda) in comparable patient populations. Likewise, 12-month survival rates for all three were similar." "This study was characterized by an unexpectedly high OS for the standard-of-care arm, with a median of 8.3 months," the authors continued. "This outcome was higher than median OS values for standard-of-care arms reported in similar studies with PD-1 inhibitors." Ongoing [...]